Keros Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Keros Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Keros Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$53M, a 34.3% decline year-over-year.
  • Keros Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$182M, a 27.4% decline year-over-year.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$153M, a 46.2% decline from 2022.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$105M, a 78.2% decline from 2021.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.7M, a 29.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$153M -$48.3M -46.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$105M -$45.9M -78.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$58.7M -$13.4M -29.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$45.4M -$33M -268% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 -$12.3M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.